Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up of participants treated with lentiviral adoptive cell therapies
NL-OMON52738Phase 2Not yet recruiting
- Sponsor
- Adaptimmune Therapeutics
- Start
- Jan 2026
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of letetresgene autoleucel, GSK3845097 and NY-ESO-1/LAGE-1a TCR-engineered T cells in cancer, Nonhematologic neoplasms and non-small cell lung cancer (NSCLC), sponsored by Adaptimmune Therapeutics. Primary endpoint: Delayed adverse events. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
letetresgene autoleucelGSK3845097NY-ESO-1/LAGE-1a TCR-engineered T cells
03
Conditions
cancerNonhematologic neoplasmsnon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON52738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52738.